Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Filippo Venturini"'
Autor:
Chiara Cremolini, Clara Montagut, Philippe Ronga, Filippo Venturini, Kensei Yamaguchi, Sebastian Stintzing, Alberto Sobrero
Publikováno v:
Frontiers in Oncology, Vol 12 (2023)
In patients with RAS wild-type metastatic colorectal cancer (mCRC), an anti-epidermal growth factor receptor (EGFR) monoclonal antibody plus chemotherapy is a standard option for treatment in the first-line setting. Patients who progress while on tre
Externí odkaz:
https://doaj.org/article/1777e610457b4d03857d820d434f40e8
Autor:
Giovanni Grignani, Vanna Chiarion Sileni, Carmine Pinto, Roberta Depenni, Nicola Fazio, Luca Galli, Dario Giuffrida, Carlo Carnaghi, Domenico Ciliberto, Domenico C. Corsi, Paola Queirolo, Elena Benincasa, Filippo Venturini, Gennaro Fazzi, Nuno Costa, Paolo Antonio Ascierto
Publikováno v:
Journal of Translational Medicine, Vol 19, Iss 1, Pp 1-11 (2021)
Abstract Background The incidence of Merkel cell carcinoma (MCC), a rare form of skin cancer with a poor prognosis, has increased in Italy in recent decades. Avelumab, an anti-programmed death ligand 1 monoclonal antibody, is approved for the treatme
Externí odkaz:
https://doaj.org/article/f52e875346f74ef69cff61e898b81684
Autor:
Filippo Venturini, Gennaro Fazzi, Dario Giuffrida, Carmine Pinto, Vanna Chiarion Sileni, Elena Benincasa, Nicola Fazio, Paolo A. Ascierto, Domenico Corsi, Luca Galli, Roberta Depenni, Giovanni Grignani, Domenico Ciliberto, Paola Queirolo, Nuno Costa, Carlo Carnaghi
Publikováno v:
Journal of Translational Medicine, Vol 19, Iss 1, Pp 1-11 (2021)
Journal of Translational Medicine
Journal of Translational Medicine
Background The incidence of Merkel cell carcinoma (MCC), a rare form of skin cancer with a poor prognosis, has increased in Italy in recent decades. Avelumab, an anti-programmed death ligand 1 monoclonal antibody, is approved for the treatment of met
Autor:
Lorenzo Antonuzzo, Marco Maruzzo, Ugo De Giorgi, Daniele Santini, Rosa Tambaro, Sebastiano Buti, Francesco Carrozza, Fabio Calabrò, Giuseppe Di Lorenzo, Giuseppe Fornarini, Roberto Iacovelli, Daniela Cullurà, Carlo Messina, Claudia Masi, Angelo Ciccia, Gennaro Fazzi, Filippo Venturini, Raffaele Colasanto, Andrea Necchi, Sergio Bracarda
Publikováno v:
Journal of Clinical Oncology. 41:469-469
469 Background: In the phase 3 JAVELIN Bladder 100 trial (NCT02603432), avelumab (anti–PD-L1) 1LM plus best supportive care (BSC) in patients (pts) with la/mUC whose disease did not progress after 1L platinum-based chemotherapy (PBC) significantly
Autor:
Emanuela Dell'Aquila, Paolo Tralongo, Chiara Carlomagno, Stefano Cordio, Cristina Granetto, Antonio Di Stasi, Gabriella Buccafusca, Domenico Germano, Silvana Leo, Filippo Venturini, Tiziana Latiano, Maurizio Di Bisceglie, Antonio Avallone, Raffaele Addeo, Francesco Giuliani, Silvia Brugnatelli, Maria Elena Stroppolo, Salvatore Bianco, Giuseppe Aprile, Gerardo Rosati, Sara Delfanti, Domenico Bilancia, Samantha Di Donato
Purpose There is no consensus on the use of cetuximab in elderly patients with metastatic colorectal cancer. To this end, a survey was carried in 17 Italian oncology centers. Methods The centers answered a 29-item questionnaire structured as follows:
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6ff221453e7f6bdf8ab6ef1105f13e67
http://hdl.handle.net/11588/789671
http://hdl.handle.net/11588/789671
Autor:
Filippo Venturini, Vincenzo Ricci, Alessio Fabozzi, Morena Fasano, Floriana Morgillo, Giuseppe Santabarbara, Flavia Cantile, Fortunato Ciardiello, Teresa Fabozzi, Ferdinando De Vita, Guido Giordano, Gaetano Aurilio
The clinical management of frail, elderly patients affected by colorectal cancer (CRC) remains a subject of debate. The present study reports the case of an elderly man with metastatic CRC (mCRC) who was successfully treated with capecitabine. The pa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f8b9491337572c2f19abda54ec204312
http://hdl.handle.net/11591/372342
http://hdl.handle.net/11591/372342
Autor:
Giulia Martini, Valentina Gambardella, Fortunato Ciardiello, Stefania Napolitano, Erika Martinelli, Filippo Venturini, Teresa Troiani
Publikováno v:
Colorectal Cancer. 3:299-308
SUMMARY The prognosis of patients harboring metastatic colorectal cancer (CRC) remains poor despite therapeutic improvements obtained in recent years thanks to new biologic agents. A resistance mechanism limits the effectiveness of current cancer the
Autor:
Gloria Barone, Claudia Bertan, Vincenzo Ricci, Luca Tondulli, Nadia Bianco, Maria Di Bartolomeo, Ilaria Bossi, Giuseppe Fanetti, Andrea Lampis, Federica Villa, Filippo de Braud, Pamela Biondani, Filippo Pietrantonio, Federica Perrone, Daris Ferrari, Antonio Ghidini, Filippo Venturini, Claudia Maggi
Publikováno v:
Cancer Biology & Therapy. 14:1098-1103
Few data are available outlining outcomes of panitumumab in advanced colorectal cancer patients benefiting from prior cetuximab-based regimens.Thirty patients with KRAS wild type metastatic colorectal cancer with clinical benefit from prior cetuximab
Autor:
Salvatore Siena, Riccardo Ricotta, Angelo Vanzulli, Michele Nichelatti, Matteo Oriani, Carolina Sarnataro, Martina Maiolani, Sara Di Bella, Mauro Moroni, Barbara Colnago, Maria Olga Giganti, Filippo Venturini, Andrea Sartore-Bianchi
Publikováno v:
Clinical Colorectal Cancer; Vol 12
We show that detection, by week-2 magnetic resonance imaging, of tumor shrinkage >10% in response to therapy with cetuximab or panitumumab for metastatic colorectal carcinoma represents an early indicator of clinical outcome because it is predictive
Autor:
Andrea Cassingena, Alessandro Belotti, Felicia Giacobbe, Alessandra Gambaro, Salvatore Siena, Alessio Amatu, Andrea Sartore-Bianchi, Katia Bencardino, Lisa Pietrogiovanna, Giovanna Marrapese, Filippo Venturini
Publikováno v:
Current Colorectal Cancer Reports. 8:272-276
The introduction into clinical practice of KRAS mutational status for selection of patients has dramatically improved the results from use of anti-EGFR monoclonal antibodies cetuximab or panitumumab for metastatic colorectal cancer. More refined sele